Cargando…

COVID-19 vaccination and antirheumatic therapy

The coronavirus disease 2019 (COVID-19) vaccination will be the largest vaccination programme in the history of the NHS. Patients on immunosuppressive therapy will be among the earliest to be vaccinated. Some evidence indicates immunosuppressive therapy inhibits humoral response to the influenza, pn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnold, Jack, Winthrop, Kevin, Emery, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989162/ https://www.ncbi.nlm.nih.gov/pubmed/33710296 http://dx.doi.org/10.1093/rheumatology/keab223

Ejemplares similares

The role of antirheumatics in patients with COVID-19
por: Nissen, Christoffer B, et al.
Publicado: (2021)

Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Costello, Ruth E, et al.
Publicado: (2020)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Antibody engineering to develop new antirheumatic therapies
por: Isaacs, John D
Publicado: (2009)

Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists
por: Kawazoe, Mai, et al.
Publicado: (2021)

COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2022)

Old and new antirheumatic drugs for the treatment of COVID-19
por: Benucci, Maurizio, et al.
Publicado: (2020)

Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2020)

INADEQUATE IMMUNE RESPONSE TO COVID-19 VACCINES IN THE PRESENCE OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)
por: KRISHNAIAH, AISHWARYA, et al.
Publicado: (2022)

Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy
por: Czekalska, Anna, et al.
Publicado: (2019)

Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study
por: Burton, Mary Jane, et al.
Publicado: (2015)

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies
por: Fazeli, Mir Sohail, et al.
Publicado: (2021)

Integrative modeling of transcriptional regulation in response to antirheumatic therapy
por: Hecker, Michael, et al.
Publicado: (2009)

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
por: TUFAN, Abdurrahman, et al.
Publicado: (2020)

Kinase inhibitors: a new class of antirheumatic drugs
por: Kyttaris, Vasileios C
Publicado: (2012)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis
por: Nguyen, Thao H. P., et al.
Publicado: (2022)

Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation
por: TUFAN, Abdurrahman, et al.
Publicado: (2021)

Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis
por: Jain, Vikramraj K., et al.
Publicado: (2017)

Ocular side effects of antirheumatic medications: a qualitative review
por: M Castillejo Becerra, Clara, et al.
Publicado: (2020)

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis
por: Plein, Sven, et al.
Publicado: (2020)

Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review
por: Hsieh, Tyng-Shiuan, et al.
Publicado: (2023)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

New antirheumatic effects of biphosphonate treatment
por: Konenkova, L, et al.
Publicado: (2001)

Note on the Action of Malakin as an Antipyretic and Antirheumatic
por: Abernethy, Robert
Publicado: (1895)

Gold Finger: Metal Jewellery as a Disease Modifying Antirheumatic Therapy!
por: Hlaing, T., et al.
Publicado: (2009)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
por: Infante, Marco, et al.
Publicado: (2022)

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs
por: Sokka, Tuulikki, et al.
Publicado: (2008)

Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
por: Hsieh, Cho-Hsun, et al.
Publicado: (2022)

The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
por: Góralczyk, Alicja, et al.
Publicado: (2020)

153 Do Hydroxychloroquine, Disease-Modifying Antirheumatic Agents or Steroids, Serve to Prevent COVID-19 Infection?
por: Keyes, D., et al.
Publicado: (2020)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Antirheumatic drugs and reproduction in women and men with chronic arthritis
por: Bazzani, Chiara, et al.
Publicado: (2015)

Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation
por: Onuoha, Shimobi C., et al.
Publicado: (2015)

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
por: Andreica, Ioana, et al.
Publicado: (2022)

Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine
por: Daïen, Claire I., et al.
Publicado: (2014)

Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
por: Scheinberg, Morton, et al.
Publicado: (2017)

Rheumatology and COVID-19 at 1 year: facing the unknowns
por: Calabrese, Leonard, et al.
Publicado: (2021)

To immunosuppress: whom, when and how? That is the question with COVID-19
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review
por: Kingsley, Gabrielle H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i6fd9rig0crpn07luh9lb0hi3j